New combo therapy aims to stall aggressive lung cancer
NCT ID NCT04745689
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 24 times
Summary
This study tests whether adding an experimental drug (AZD2811) to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer from growing after initial treatment. About 31 adults with this aggressive cancer will receive the combination as maintenance therapy. The goal is to see if this approach improves how long people live without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Grand Rapids, Michigan, 49503, United States
-
Research Site
Bydgoszcz, 85-796, Poland
-
Research Site
Olsztyn, 10-357, Poland
-
Research Site
Poznan, 60-693, Poland
-
Research Site
Cheongju-si, 28644, South Korea
-
Research Site
Jinju, 52727, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Seville, 41071, Spain
-
Research Site
Valencia, 46015, Spain
Conditions
Explore the condition pages connected to this study.